174 related articles for article (PubMed ID: 21863477)
1. Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug.
Morgen M; Bloom C; Beyerinck R; Bello A; Song W; Wilkinson K; Steenwyk R; Shamblin S
Pharm Res; 2012 Feb; 29(2):427-40. PubMed ID: 21863477
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
Liu Y; Sun C; Hao Y; Jiang T; Zheng L; Wang S
J Pharm Pharm Sci; 2010; 13(4):589-606. PubMed ID: 21486533
[TBL] [Abstract][Full Text] [Related]
3. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations.
Guzmán HR; Tawa M; Zhang Z; Ratanabanangkoon P; Shaw P; Gardner CR; Chen H; Moreau JP; Almarsson O; Remenar JF
J Pharm Sci; 2007 Oct; 96(10):2686-702. PubMed ID: 17518357
[TBL] [Abstract][Full Text] [Related]
4. Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation.
Nguyen TH; Tan A; Santos L; Ngo D; Edwards GA; Porter CJ; Prestidge CA; Boyd BJ
J Control Release; 2013 Apr; 167(1):85-91. PubMed ID: 23353808
[TBL] [Abstract][Full Text] [Related]
5. Influence of microcrystal formulation on in vivo absorption of celecoxib in rats.
Nasr M
AAPS PharmSciTech; 2013 Jun; 14(2):719-26. PubMed ID: 23543607
[TBL] [Abstract][Full Text] [Related]
6. Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib.
Tan A; Davey AK; Prestidge CA
Pharm Res; 2011 Sep; 28(9):2273-87. PubMed ID: 21560021
[TBL] [Abstract][Full Text] [Related]
7. In situ intestinal permeability and in vivo oral bioavailability of celecoxib in supersaturating self-emulsifying drug delivery system.
Song WH; Yeom DW; Lee DH; Lee KM; Yoo HJ; Chae BR; Song SH; Choi YW
Arch Pharm Res; 2014 May; 37(5):626-35. PubMed ID: 23852645
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization and in vitro studies of celecoxib-loaded poly(ortho ester) nanoparticles targeted for intraocular drug delivery.
Palamoor M; Jablonski MM
Colloids Surf B Biointerfaces; 2013 Dec; 112():474-82. PubMed ID: 24103464
[TBL] [Abstract][Full Text] [Related]
9. Application of a biphasic test for characterization of in vitro drug release of immediate release formulations of celecoxib and its relevance to in vivo absorption.
Shi Y; Gao P; Gong Y; Ping H
Mol Pharm; 2010 Oct; 7(5):1458-65. PubMed ID: 20704265
[TBL] [Abstract][Full Text] [Related]
10. Modification of microenvironmental pH of nanoparticles for enhanced solubility and oral bioavailability of poorly water-soluble celecoxib.
Ran Woo M; Bak YW; Cheon S; Suk Kim J; Hun Ji S; Park S; Woo S; Oh Kim J; Giu Jin S; Choi HG
Int J Pharm; 2024 Jun; 659():124179. PubMed ID: 38692498
[TBL] [Abstract][Full Text] [Related]
11. Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis.
Lee Y; Kim H; Kim W; Yoon JH; Jeong SH; Jung Y
J Drug Target; 2012 Jul; 20(6):524-34. PubMed ID: 22632102
[TBL] [Abstract][Full Text] [Related]
12. Influence of polymers on the bioavailability of microencapsulated celecoxib.
Homar M; Ubrich N; El Ghazouani F; Kristl J; Kerc J; Maincent P
J Microencapsul; 2007 Nov; 24(7):621-33. PubMed ID: 17763056
[TBL] [Abstract][Full Text] [Related]
13. Development of a chitosan-derivative micellar formulation to improve celecoxib solubility and bioavailability.
Mennini N; Furlanetto S; Bragagni M; Ghelardini C; Di Cesare Mannelli L; Mura P
Drug Dev Ind Pharm; 2014 Nov; 40(11):1494-502. PubMed ID: 23992553
[TBL] [Abstract][Full Text] [Related]
14. Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ε-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats.
Ghorab DM; Amin MM; Khowessah OM; Tadros MI
Drug Deliv; 2011; 18(7):523-35. PubMed ID: 21793779
[TBL] [Abstract][Full Text] [Related]
15. Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process.
Ha ES; Choo GH; Baek IH; Kim MS
Molecules; 2014 Dec; 19(12):20325-39. PubMed ID: 25486246
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo characteristics of celecoxib in situ formed suspensions for intra-articular administration.
Larsen SW; Frost AB; Ostergaard J; Thomsen MH; Jacobsen S; Skonberg C; Hansen SH; Jensen HE; Larsen C
J Pharm Sci; 2011 Oct; 100(10):4330-7. PubMed ID: 21598256
[TBL] [Abstract][Full Text] [Related]
17. A novel three-dimensional large-pore mesoporous carbon matrix as a potential nanovehicle for the fast release of the poorly water-soluble drug, celecoxib.
Zhang Y; Wang H; Li C; Sun B; Wang Y; Wang S; Gao C
Pharm Res; 2014 Apr; 31(4):1059-70. PubMed ID: 24287624
[TBL] [Abstract][Full Text] [Related]
18. Modeling of corneal and retinal pharmacokinetics after periocular drug administration.
Amrite AC; Edelhauser HF; Kompella UB
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):320-32. PubMed ID: 18172109
[TBL] [Abstract][Full Text] [Related]
19. Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells.
Kim TH; Jeong YI; Jin SG; Pei J; Jung TY; Moon KS; Kim IY; Kang SS; Jung S
Int J Nanomedicine; 2011; 6():2621-31. PubMed ID: 22114493
[TBL] [Abstract][Full Text] [Related]
20. The mechanism for increasing the oral bioavailability of poorly water-soluble drugs using uniform mesoporous carbon spheres as a carrier.
Wang T; Zhao P; Zhao Q; Wang B; Wang S
Drug Deliv; 2016; 23(2):420-8. PubMed ID: 24870199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
